Orphazyme20.jpg

INVESTORS & MEDIA

INVESTORS & MEDIA

Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative rare diseases.

We are committed to providing relevant, accurate and timely information to investors and the financial community. Orphazyme is listed on Nasdaq Copenhagen (ORPHA) and Nasdaq US (ORPH).

 

Latest Announcements

Share Price

Read more

Upcoming Events

Date Event Details
Summary Toggle 18/06/2021
Time: 8.00 AM CET
Confirmation Code: 2889481
United Kingdom, local........ +44 (0) 8444819752
Denmark, Copenhagen....... +45 32720417
France, Paris........................ +33 (0) 170700781
Netherlands, Amsterdam... +31 (0) 207956614
Sweden, Stockholm............ +46 (0) 856618467
Standard International....... +44 (0) 2071 928338
United States, New York    +1 6467413167
 
Summary Toggle 18/06/2021
Time: 2.00 PM CET
Confirmation Code: 9349928
United Kingdom, local........ +44 (0) 8444819752
Denmark, Copenhagen....... +45 32720417
France, Paris........................ +33 (0) 170700781
Netherlands, Amsterdam... +31 (0) 207956614
Sweden, Stockholm............ +46 (0) 856618467
Standard International....... +44 (0) 2071 928338
United States, New York    +1 6467413167
 
Summary Toggle 24/08/2021

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site.

Sign up here

IR Contact

anders

Anders Vadsholt

CFOTel: (+45) 28 98 90 55E-mail: afv@orphazyme.com